Company / Cash & Equivalents
MetLife Cash & Equivalents History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Cash & Equivalents
$22.0B
FY2025
5-year range
$20.0B / $22.0B
FY2021-FY2025
Trend
+9.8%
vs FY2024
Sector context
#4 of 258
Financials
What the data says
Among 258 Financials companies, MetLife is in the top 2% for cash & equivalents. Improved from $20.6B to $22.0B over the past 2 years.
Based on SEC 10-K filings.
$22.0B in FY2025 with a 5-year CAGR of +2.2%. Top quartile in the Financials sector.
Improved from $20.6B to $22.0B over the past 2 years.
Financials sector context is included.
Cash & Equivalents over time
Growth rates
- 3-Year CAGR
- +2.9%
- 5-Year CAGR
- +2.2%
- 10-Year CAGR
- -
Sector benchmark
Top 2% in FinancialsTop 2% of 258This company $22.0B Sector average $2.8B
▼
+684.7% above sector average
Key checks
Key Insights
- 5-year CAGR of +2.2%, indicating consistent growth.
- In FY2025, cash & equivalents increased 9.8% year-over-year.
- Ranks #4 out of 258 companies in the Financials sector.
- Lowest cash & equivalents in the period was in FY2016.
Company context
Key Data Points
- Altman Z-Score 0.20 (distress zone, below 1.8 threshold)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Cash & EquivalentsValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $22.0B | +9.8% |
| FY2024 | $20.1B | -2.8% |
| FY2023 | $20.6B | +2.2% |
| FY2022 | $20.2B | +0.7% |
| FY2021 | $20.0B | +1.3% |
| FY2020 | $19.8B | +19.3% |
| FY2019 | $16.6B | +4.9% |
| FY2018 | $15.8B | +24.6% |
| FY2017 | $12.7B | +0.4% |
| FY2016 | $12.7B | +13.1% |
As of FY2025 · SEC 10-K Annual Filings · Updated Mar 9, 2026